Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P110042/S216

EMBLEM Subcutaneous Implantable Cardioverter Defibrillator (S-ICD) high voltage (HV) Capacitor

BOSTON SCIENTIFIC CORPORATION · Decision date Oct 2, 2026

MEDTECHLEDGER EXPLANATIONP110042/S216

What did the FDA decide?

FDA recorded a 30-day notice decision, OK30, dated 2026-10-02 for P110042/S216, a supplement to Boston Scientific Corporation's EMBLEM Subcutaneous Implantable Cardioverter Defibrillator (S-ICD) high voltage (HV) Capacitor. The supplement reason is listed as a process change affecting manufacturer, sterilizer, packager or supplier. The recorded statement describes adjusting manufacturing steps and modifying laser equipment software for the HV capacitors in EMBLEM S-ICD devices.

This action concerns the capacitor component and its fabrication process rather than a new approval of the complete S-ICD system. The device category is implantable cardioverter defibrillator (non-CRT), specialty cardiovascular, product code LWS. The source record includes no documents, so the specific process parameters, software changes and any supporting data are not available here; clinical or legal implications of the change cannot be assessed from these fields alone.

FDA approval order statement

to adjust the manufacturing steps and modify the laser equipment software for the HV capacitors in EMBLEM SICD devices
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Oct 2, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P110042/S216
Regulatory pathway
PMA supplement
Product code
LWS
Decision code
OK30
Decision date
Oct 2, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Implantable cardioverter defibrillator (non-CRT).

Product code
LWS
FDA device class
3

For the original device and its historical approval scope, see PMA P110042. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P110042 · Original PMA

    SUBCUTANEOUS IMPLANTABLE DEFIBRILLATOR (S-ICD) SYSTEM

  2. P110042/S216 received

    Application receipt date recorded by FDA.

  3. P110042/S216 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P110042. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P110042

Product / regulatory recordCompanyPathwayDecision dateSource
BOSTON SCIENTIFIC CORPORATIONPMA approvalSep 28, 2012FDA

Explore the linked device profile

Other records with product code LWS

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Boston Scientific Corporation

Headquarters
Not reported
FDA applicant address
4100 Hamline Ave. N, St Paul, MN, 55112

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records